Development of novel medicines using high resolution native mass spectrometry of intact protein assemblies
OMass is an Oxford University spin-out that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
Date: 7 September 2021, 12:00 (Tuesday, 20th week, Trinity 2021)
Venue: Zoom
Speaker: Dr Katharina Duerr (OMass Therapeutics)
Organising department: Divisional Office (MSD)
Organisers: Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
Host: Sheena Lee (MSD Business Partnerships Office)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url:
Cost: Free
Audience: Members of the University of Oxford and the Biotech/Pharma industry
Editor: Sheena Lee